Salud financiera de hoja de balance de Merus
Salud financiera controles de criterios 6/6
Merus tiene un patrimonio de los accionistas total de $356.3M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $455.5M y $99.2M respectivamente.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$337.50m |
| Patrimonio | US$349.45m |
| Total pasivo | US$148.64m |
| Activos totales | US$498.08m |
Actualizaciones recientes sobre salud financiera
Merus (NASDAQ:MRUS) Is In A Good Position To Deliver On Growth Plans
May 10
We Think Merus (NASDAQ:MRUS) Needs To Drive Business Growth Carefully
Sep 19Is Merus (NASDAQ:MRUS) In A Good Position To Invest In Growth?
May 24Merus (NASDAQ:MRUS) Is In A Strong Position To Grow Its Business
Apr 25We're Not Worried About Merus' (NASDAQ:MRUS) Cash Burn
Nov 25We're Not Very Worried About Merus' (NASDAQ:MRUS) Cash Burn Rate
Jul 02Recent updates
Merus (NASDAQ:MRUS) Is In A Good Position To Deliver On Growth Plans
May 10Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement
Mar 01Merus N.V.'s (NASDAQ:MRUS) Shares Climb 30% But Its Business Is Yet to Catch Up
Feb 01Merus Stock: Rally Seems Overdone
Jan 23Are Investors Undervaluing Merus N.V. (NASDAQ:MRUS) By 45%?
Jan 14Risks To Shareholder Returns Are Elevated At These Prices For Merus N.V. (NASDAQ:MRUS)
Dec 18We Think Merus (NASDAQ:MRUS) Needs To Drive Business Growth Carefully
Sep 19Merus N.V.'s (NASDAQ:MRUS) Business Is Yet to Catch Up With Its Share Price
Jun 20Is Merus (NASDAQ:MRUS) In A Good Position To Invest In Growth?
May 24Merus N.V. (NASDAQ:MRUS) Shares Could Be 26% Below Their Intrinsic Value Estimate
Feb 08Merus GAAP EPS of -$0.13 beats by $0.49, revenue of $12.68M beats by $2.23M
Aug 08Merus N.V. initiated with Buy at Stifel based on three bispecific antibodies
Aug 02Merus: Precision Oncology Pioneer Continues To Execute In The Clinic
Jun 30Need To Know: Analysts Are Much More Bullish On Merus N.V. (NASDAQ:MRUS)
May 14Merus (NASDAQ:MRUS) Is In A Strong Position To Grow Its Business
Apr 25New Forecasts: Here's What Analysts Think The Future Holds For Merus N.V. (NASDAQ:MRUS)
Mar 03We're Not Worried About Merus' (NASDAQ:MRUS) Cash Burn
Nov 25News Flash: Analysts Just Made A Sizeable Upgrade To Their Merus N.V. (NASDAQ:MRUS) Forecasts
Aug 08Calculating The Intrinsic Value Of Merus N.V. (NASDAQ:MRUS)
Jul 28We're Not Very Worried About Merus' (NASDAQ:MRUS) Cash Burn Rate
Jul 02Merus posts positive efficacy data from early-stage zenocutuzumab cancer study
Jun 04Merus EPS misses by $0.10, misses on revenue
May 06Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($368.8M) de MRUS superan a sus pasivos a corto plazo ($69.1M).
Pasivo a largo plazo: Los activos a corto plazo de MRUS ($368.8M) superan a sus pasivos a largo plazo ($30.1M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: MRUS está libre de deudas.
Reducción de la deuda: MRUS no tenía deudas hace 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: MRUS tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: MRUS dispone de suficiente cash runway para 2 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 22.8% cada año.